Spots Global Cancer Trial Database for Title XELOX FOR SALIVARY GLAND CANCERS

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Title XELOX FOR SALIVARY GLAND CANCERS

Official Title: Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Patients With Locally Advanced, Incurable, Salivary Gland Cancers

Study ID: NCT00101075

Conditions

Head and Neck Cancer

Interventions

Capecitabine

Oxaliplatin

Study Description

Brief Summary: The goal of this clinical research study is to find out how effective oxaliplatin and capecitabine are against advanced cancer of the salivary gland. The safety of this treatment as well as how long the cancer responds or stays in a stable state due to the treatment will also be studied.

Detailed Description: This is a study of two investigational agents called oxaliplatin and capecitabine. Investigational agents have not received Food and Drug Administration (FDA) approval for the way they are being used in this study. This means an investigation drug is still under study to determine what a safe dose is, what the side effects are and whether or not it is effective in the disease or condition being studied. Oxaliplatin and capecitabine are chemotherapy agents that have been approved by the FDA for use in other cancers.